AbbVie’s etentamig delivered a 74% response rate and reduced the risk of progression or death by 60% in the Phase 3 CERVINO trial. Its real competitive proposition, however, may be operational: monthly dosing after a single step-up dose could help move BCMA-directed T-cell therapy beyond specialist centres.
Arlocabtagene autoleucel met response and complete-response endpoints in patients already exposed to immunomodulators, proteasome inhibitors, anti-CD38 treatment and BCMA therapy, positioning GPRC5D as a possible next CAR T target after increasingly crowded myeloma treatment sequences.
Find out how CARsgen’s CT0596 and CT1190B data could reshape the allogeneic CAR T race in cancer therapy.
UCB is paying heavily for early autoimmune science. Candid tests whether T-cell engagers can move beyond oncology into immune reset.
Can CTA313 redefine lupus treatment with CAR-T? Explore what Imviva Biotech’s early data means for autoimmune therapy innovation.
Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.
Find out how Tempest Therapeutics, Inc.’s CAR-T strategy could shape the next phase of cell therapy competition and multiple myeloma innovation.
Innovent Biologics unveiled preclinical IBI3055 data in autoimmune disease. Read what this could change for immune-reset therapies.
Gilead Sciences acquires Ouro Medicines for up to $2.18bn, adding BCMA T cell engager gamgertamig to its inflammation pipeline. Analysis of what the deal reveals.
FDA approves J&J's teclistamab plus daratumumab for relapsed myeloma from second line. Analyse the MajesTEC-3 data, safety profile, and what this changes for treatment.